Has Jitendra Vasandani, MD received payments from drug or device companies?

Yes. Drug and device makers reported $6,372,635 in general payments to Jitendra Vasandani, MD across 3,531 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jitendra Vasandani, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jitendra Vasandani, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jitendra Vasandani, MD

Rheumatology · Lubbock, TXNPI 1194707406

Payments from drug & device makers

$6,372,635in general payments, 2019–2025

Across 3,531 payments — averaging $1804.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sun Pharmaceutical Industries Inc.$2.3M
AbbVie$1.5M
GSK$887K
Amgen$504K
E.r. Squibb & Sons, L.L.C.$306K
Eli Lilly$179K
plus $646K from 41 others

$78,092in research payments, 2019–2025

Across 5 payments — averaging $15,618 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$45K
Sanofi US Services Inc.$33K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sun Pharmaceutical Industries Inc.	640	$2,348,096
AbbVie	460	$1,501,996
GSK	391	$887,306
Amgen(2 entities)	595	$503,845
E.r. Squibb & Sons, L.L.C.	129	$306,473
Eli Lilly	2	$179,008
Takeda Pharmaceuticals U.S.A., Inc.	23	$159,713
Janssen Research & Development, LLC	27	$159,115
Bristol Myers Squibb	33	$83,411
UCB SA	4	$78,434
Sanofi US Services Inc.	9	$68,876
Regeneron	25	$45,053
Novartis	171	$18,669
UCB, Inc.	196	$9,596
Gilead	1	$6,500
Johnson & Johnson(2 entities)	143	$3,285
AstraZeneca(2 entities)	79	$2,607
Lilly USA, LLC	81	$1,457
Pfizer	118	$1,302
Sanofi	42	$1,198
Mallinckrodt Hospital Products Inc.	31	$1,045
Radius Health, Inc.	66	$992
Genentech USA, Inc.	77	$988
ANI Pharmaceuticals, Inc.	36	$743
Boehringer Ingelheim	30	$696
Pacira Therapeutics, Inc.	52	$517
Janssen Scientific Affairs, LLC	4	$277
Daiichi Sankyo Inc.	13	$215
Cardinal Health 110 LLC	2	$200
Sandoz	8	$185
Sanofi-aventis U.S. LLC	7	$160
Actelion Pharmaceuticals US, Inc.	3	$95
Sobi, Inc	4	$93
Merck	1	$70
Antares Pharma, Inc.	5	$68
Bioventus LLC	3	$50
Ultragenyx Pharmaceutical Inc.	3	$45
Organon	5	$43
Mylan Institutional Inc.	2	$34
Mallinckrodt Enterprises LLC	2	$33
Iroko Pharmaceuticals, LLC	1	$28
Ferring Pharmaceuticals Inc.	2	$28
Arbor Pharmaceuticals, Inc.	1	$21
Aurinia Pharma U.S., Inc.	1	$20
Idorsia Pharmaceuticals US Inc	1	$19
Alvogen Inc	1	$17
Tersera Therapeutics LLC	1	$14

How this compares

$6,372,635 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas →

Medicare billing

Part B allowed, 2024

$4,509,421

Medicare patients

1,001

Services billed

312,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Lubbock

Paul PickrellAustin$40.9M
Atul SinghalMesquite$13.9M
Shaikh AliTomball$9.8M
Dhiman BasuColleyville$6.2M
Tamar BrionezThe Woodlands$5.2M
Philip WallerHouston$4.9M
John CushDallas$3.9M
Sabeen NajamBaytown$3.6M
Sanjay ChabraEl Paso$3.6M
Fehmida ZahabiPlano$2.5M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →